STAT· @statnews · X·· 2026-10-16精选AI 评分58
AI 导读
Verastem Oncology的KRAS G12D抑制剂在1/2期试验中,用于8例接受二线治疗的转移性胰腺癌患者,客观缓解率为50%。该结果来自STAT News的报道,更多数据细节见原文链接。
推荐理由
该早期试验在二线转移性胰腺癌中给出50%缓解率,读者可据此判断KRAS G12D靶点的初步信号。
正文
In a Phase 1/2 trial, Verastem Oncology's KRAS G12D inhibitor produced a 50% response rate among eight patients with metastatic pancreatic cancer receiving it as second-line therapy.
Read more details about the results here: https://trib.al/5Bertdo
来源:STAT · x.com